Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)
Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if giving durvalumab alone or in
combination with tremelimumab to patients with oropharynx carcinoma before standard-of-care
surgery can help to control the disease.
The safety of these drugs will also be studied.